Background and Case Definition
A foreign medical-device manufacturer has early interest from Chinese hospitals and distributors. It must choose whether to appoint a distributor, establish a wholly owned commercial company or form a deeper partnership for registration, service and later localization.
The case is illustrative. It replaces a fictional German company, invented approval time, cost and percentage improvement. The decision is based on the medical-device regulatory framework, customer evidence and the capabilities each route must provide.
Challenge: Four Different Needs
The company needs product registration, an importer and channel, installation and service, and reliable post-market information. One partner may claim to provide all four but have strength in only sales. Management must preserve manufacturer responsibility, technical control and access to complaints while building enough local capability to serve hospitals.
The product configuration includes hardware, software, accessories and consumables. Any entry model must support the same approved intended use, labeling and quality system. Commercial pressure cannot change the registered product through informal local customization.
Approach: Validate the Regulatory Path First
The team confirms classification, registration authority, testing, clinical evaluation or investigation, overseas registrant responsibilities and China agent role. It performs a gap analysis against the current NMPA requirements and obtains quotations for product-specific work.
This prevents the distributor from defining the regulatory strategy around a sales deadline. The manufacturer owns the technical position and keeps copies of all submissions, authority correspondence and certificates.
Option 1: Distributor-Led Entry
A distributor can provide hospital coverage, tender experience, logistics and collections. The manufacturer verifies legal identity, licenses, sub-distributors, customer base, service staff, regulatory experience and compliance history. Exclusivity is limited and tied to measurable performance.
The contract gives the manufacturer access to complaints, adverse events, field actions and customer feedback. Registration and platform accounts should not become commercial hostages. Distributor margin is evaluated together with training, demonstration, inventory, service and payment obligations.
Option 2: Wholly Owned Commercial Company
A wholly owned company can employ staff, contract locally, invoice, manage service and protect customer access. It requires greater fixed cost and management capability. It does not remove NMPA registration, importer, distribution or product responsibilities.
The company may still use non-exclusive distributors while controlling key accounts and post-market systems. Registered capital and funding are based on payroll, premises, demonstration equipment, inventory, service and working capital.
Option 3: Strategic Partner or Joint Venture
A deeper partner may be justified for manufacturing, a licensed capability, customer access or substantial technical service. Every contribution is verified and documented. Governance covers budgets, key officers, related-party transactions, quality, technology, data and changes to the registered product.
The manufacturer limits technology rights to the approved business. Background IP, improvements, tooling, software and post-termination use are allocated before transfer. A joint venture is not selected merely to create an appearance of localization.
Customer and Service Validation
The team interviews clinicians, biomedical engineering, procurement and finance at target institutions. It identifies clinical use, competing products, installation, training, service response, tender and budget. Letters of interest are separated from funded procurement routes.
Service readiness is tested with response times, spare parts, escalation, calibration and engineer qualifications. The product cannot be launched safely if the distributor has sales reach but no technical capability.
Quality and Post-Market Governance
Complaint, adverse-event, recall and field-correction procedures connect every channel participant to the manufacturer and responsible China parties. Records are accessible and auditable. Sales personnel are trained to recognize safety information rather than classify every report as a customer-service issue.
Changes to software, supplier, manufacturing site, labeling or intended use follow formal assessment. Local customization does not bypass the registered configuration.
Data and Cybersecurity
Connected devices can generate patient, clinical and device data. The operating model maps hosting, administrator access, remote support, logs and cross-border transfers. Overseas engineers receive minimum necessary access through the applicable Chinese route.
Contracts allocate data roles among hospital, distributor, service provider and manufacturer. A commercial partner cannot consent on behalf of patients or institutions beyond its authority.
Financial Comparison
The distributor route has lower fixed cost but a larger channel margin and less direct control. A wholly owned route adds payroll, systems and compliance while preserving customer access. A joint venture adds governance and technology risk and should deliver a capability worth those costs.
The model includes registration, testing, clinical evidence, agent, import, demonstration, service, tender, inventory and payment periods. No route receives an invented universal approval time or cost.
Implementation Governance
Regulatory, quality, commercial, service, legal and finance leaders share one implementation schedule. Decisions about claims, product version, channel, importer, data access and service are recorded with an owner. The launch committee can stop a sale when the approved configuration, trained service coverage or post-market reporting route is not ready.
External partners report against the same schedule and evidence standards. They cannot declare approval, hospital access or service readiness through a sales presentation alone. Material changes return to the responsible manufacturer and China management before implementation.
Partner Transition and Exit
The company plans for distributor replacement, end of exclusivity or later transfer of key accounts to a wholly owned team. Contracts cover inventory, customer communication, technical records, complaints, platform accounts, data and ongoing service. Regulatory responsibilities continue during transition and are not suspended by a commercial dispute.
Result: A Staged Hybrid Route
The company chooses a staged route after comparing evidence. It retains control of regulatory and quality strategy, appoints qualified non-exclusive channel support for early market validation, and builds a small wholly owned service and key-account capability when demand supports it. Manufacturing or a joint venture remains a later decision gate.
Management Lessons
- Separate registration, distribution, service and localization decisions.
- Keep manufacturer access to the complete regulatory and safety record.
- Verify partner licenses, customers and technical staff.
- Use staged investment tied to customer and regulatory evidence.
- Do not trade product control for an unsupported promise of speed.
Official Sources
- National Health Commission: Regulations for the Supervision and Administration of Medical Devices
- National Medical Products Administration: Measures for Medical Device Registration and Filing
- State Administration for Market Regulation: Company Law
- Cyberspace Administration of China: cross-border data flow provisions
